Mechanistically, during the onset of arthritis, IL-23 promotes IL-21 and IL-22 production by Th17 cells, which suppresses St6gal1 expression in plasma cells, resulting in increased levels of the pathogenic form of IgG glycosylation. This evidence concerns the gene IL23A and arthritic joint disease.